2011
Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study Results from the 6-month continuation phase
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Perkins BA, Welsh JB, Willi SM, Wood MA, . Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study Results from the 6-month continuation phase. Diabetes Care 2011, 34: 2403-2405. PMID: 21933908, PMCID: PMC3198292, DOI: 10.2337/dc11-1248.Peer-Reviewed Original Research
2010
The Cost-Effectiveness of Continuous Glucose Monitoring in Type 1 Diabetes
Huang ES, O'Grady M, Basu A, Winn A, John P, Lee J, Meltzer D, Kollman C, Laffel L, Tamborlane W, Weinzimer S, Wysocki T, . The Cost-Effectiveness of Continuous Glucose Monitoring in Type 1 Diabetes. Diabetes Care 2010, 33: 1269-1274. PMID: 20332354, PMCID: PMC2875436, DOI: 10.2337/dc09-2042.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioContinuous glucose monitoringType 1 diabetic patientsImproved glucose controlCost-effectiveness analysisGlucose controlDiabetic patientsGlucose monitoringBenefits of CGMType 1 diabetes complicationsTest strip useType 1 diabetesCost-effectiveness ratioStandard glucose monitoringMicrovascular complicationsDiabetes complicationsTrial populationSocietal cost-effectiveness analysisGlycemic benefitsLong-term effectsMAIN OUTCOMELife benefitsQALY thresholdStrip useTrial data